- Home
- ERAS vs MBLY Comparison
ERAS vs MBLY Comparison
Compare ERAS & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERAS | MBLY |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 7.3B |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ERAS | MBLY |
|---|---|---|
| Price | $16.34 | $8.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 20 |
| Target Price | ★ $14.25 | $14.13 |
| AVG Volume (30 Days) | ★ 3.3M | 3.3M |
| Earning Date | 05-08-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 36.23 | ★ 87.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,894,000,000.00 |
| Revenue This Year | N/A | $4.91 |
| Revenue Next Year | N/A | $13.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 14.51 |
| 52 Week Low | $1.53 | $6.47 |
| 52 Week High | $24.28 | $15.81 |
Technical Indicators
Market Signals| Indicator | ERAS | MBLY |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 47.89 |
| Support Level | $12.36 | $8.43 |
| Resistance Level | $18.71 | $9.55 |
| Average True Range (ATR) | 1.20 | 0.28 |
| MACD | -0.24 | -0.02 |
| Stochastic Oscillator | 15.04 | 34.54 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Moovit. The solutions provided by the company are: Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.